BioSpace News Archive

NKGen Biotech, Inc. announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details around its NK cell therapy in neurodegenerative disease.

Lumos Pharma, Inc. (NASDAQ:LUMO) announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will report financial results for the first quarter 2024 on Thursday, May 9, 2024.

Longeveron Inc. announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in October 2023 and April 2024.

Bio-Path Holdings, Inc. announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered direct offering priced at-the-market under Nasdaq rules.

The global cell and gene therapy clinical trials market was evaluated at US$ 11.57 billion in 2023 and is expected to attain around US$ 40.98 billion by 2032

Partner Therapeutics, Inc. announced publication of a comprehensive review by Dougan et al. in Cancers summarizing the mechanistic rationale and pre-clinical and clinical data regarding the use of Leukine to manage gastrointestinal immune-related adverse events for patients taking immune checkpoint inhibitors for the treatment of cancer.